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ABSTRACT 
Background: Blood pressure and anti-hypertensive treatment generally increase with age but 
there is uncertainty concerning the value of treatment at very advanced ages.
Objectives: To estimate cost-effectiveness of anti-hypertensive treatment (AHT) in people 
aged 80 years and over.
Methods: A Markov model compared AHT with no blood pressure treatment for prevention 
of cardiovascular disease. Outcomes were new stroke, coronary heart disease and diabetes, 
with falls included as a potential complication of AHT. Costs were evaluated from a health 
system perspective. Incidence, mortality and costs of health care utilisation were estimated 
from linked primary and secondary care electronic health records for 98,220 individuals aged 
80 and older. Clinical effectiveness estimates were from the Hypertension in the Very Elderly 
Trial (HYVET). Deterministic and probabilistic sensitivity analyses were conducted.
Results: In the base case, AHT was associated with an additional 725 quality adjusted life 
years (QALYs) and £4.3 million per 1000, with an incremental cost-effectiveness ratio 
(ICER) of £5977 per QALY. The ICER was most sensitive to the cost of falls and relative 
risk reduction in stroke incidence. Probabilistic sensitivity analysis gave 95% uncertainty 
intervals: £5057 to £8398 per QALY in men and £4955 to £8218 per QALY in women. AHT 
for secondary prevention in participants with CHD gave an ICER of £9903 per QALY.
Conclusions: AHT is estimated to be cost-effective in individuals aged 80 years and over, 
even if health benefits are smaller or side effects costlier than in the base case. Benefits and 
harms for vulnerable sub-groups require further evaluation. 
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Highlights
What is already known about the topic?
 Blood pressure levels and treatment with anti-hypertensive therapy (AHT) increase 
with age but there is uncertainty concerning the value of treatment at very advanced 
ages beyond 80 years.
What does the paper add to existing knowledge?
 AHT in over-80s was associated with 725 incremental quality adjusted life years 
(QALYs) and incremental health care costs of £4.3 million per 1000, resulting in an 
incremental cost-effectiveness ratio (ICER) of £5977 per QALY. The ICER estimate 
was sensitive to the costs of treatment-associated falls but AHT was considered cost-
effective in over-80s even if side effects are more costly than in the base case. 
What insights does the paper provide for informing health care-related decision making? 
 Treatment for hypertension over the age of 80 years is cost-effective after accounting 
for falls, with a high probability of health benefit at acceptable cost even under less 
favourable assumptions. These findings may contribute new information to inform 
guidelines for treating hypertension in over-80s.
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INTRODUCTION
High blood pressure (BP), or clinical hypertension, is the most important risk factor for 
cardiovascular diseases (CVDs) including stroke, heart failure and myocardial infarction 1 2. 
Blood pressure levels generally increase with age 3 4 and the prevalence of hypertension and 
treatment with antihypertensive therapy (AHT) is very high in older adults, despite 
uncertainties concerning the risks and benefits of treatment at advanced ages.5 6 The 
occurrence of CVD has also shifted to older ages. CVDs now represent one of the most costly 
disease categories, with direct costs of $555 billion in the United States (US) in 2016 and £19 
billion annually in the United Kingdom (UK).7 8
While many studies have provided evidence of the effectiveness of AHT for cardiovascular 
prevention in middle-aged adults, the evidence at older ages is less clear. Several studies have 
reported benefits of AHT in people over 60 years, particularly for prevention of stroke, 9-12 
but potential benefits in people aged over 80 years are less well-established. The 
HYpertension in the Very Elderly Trial (HYVET) 13 is the only placebo-controlled trial to 
evaluate the effectiveness  of AHT in participants aged 80 years or older. The HYVET trial 
provided evidence of reduction in stroke incidence and mortality, as well as lower all-cause 
mortality, with AHT. 13 Eligible participants in HYVET may have had less comorbidity than 
in a general population sample of older adults but the HYVET investigators found no 
evidence that the intervention effect depended on frailty level. 14 In the Systolic Blood 
Pressure Intervention Trial (SPRINT), which employed a treat-to-target BP strategy in 
participants aged 75 and over, AHT was associated with lower rates of CVD events and 
lower all-cause mortality, but intervention was associated with slightly higher rates of kidney 
injury and syncope.15 Non-randomised epidemiological studies report that comorbidity and 
frailty are frequent in this age-group, consequently adverse effects including orthostatic 
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hypotension and falls assume greater importance at older ages.5 16 Many authors emphasize 
the importance of considering adverse events, cautioning against aggressive BP-lowering in 
the very elderly.17 18
Guidelines for treating hypertension in older people are inconsistent. The American Heart 
Association (AHA) and American College of Cardiology (ACC) recently recommended that 
the threshold systolic blood pressure (SBP) level for initiating treatment in over-65s should 
be reduced from 140 mm Hg to 130 mm Hg. 19 20 In contrast, the American College of 
Physicians (ACP) and the American Academy of Family Physicians (AAFP) recommend the  
SBP threshold of 150 mm Hg in over-60s 21, consistent with the National Institute for Care 
Excellence (NICE) recommendations in the UK for over-80s.22 In the absence of sufficient 
evidence, it is uncertain which individuals should be classified as hypertensive and treated 
with AHT. Improved evidence on the cost-effectiveness of AHT in over-80s may help to 
inform this debate.
One previous health economic evaluation 23 was conducted in the age-group over 80 years, 
evaluating cost-effectiveness of AHT from a Swiss health care perspective. This Swiss study 
used life-years as its main health outcome and concluded that treatment was cost-effective. 
However, the data available for analysis suffered from several limitations. The study did not 
estimate quality adjusted life years as a preferred outcome; costs were extrapolated from 
studies in younger age-groups; and adverse events were not accounted for. The present study 
aimed to add to this limited evidence base, by estimating the cost-effectiveness of AHT in 
individuals aged 80 years and older. The study draws on empirical data from the UK through 
epidemiological analysis of electronic health records. These analyses provided population-
based estimates for the probability of transitioning between each of the model’s health states. 
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Analyses also provided empirical estimates for health care resource use. Potential adverse 
events from treatment were accounted for in the model through the inclusion of falls. 
METHODS
Intervention comparators
Cost-effectiveness of universal AHT, using a diuretic and an ACE-inhibitor if needed, was 
evaluated in comparison with no AHT. A population-wide strategy in which all individuals 
over 80 years are treated is justified by clinical guidelines, which generally recommend that 
treatment for hypertension should be based on individuals’ overall 10-year CVD risk.19 22 24-26 
Increasing age is the strongest predictor of risk, with all individuals aged 80 years and older 
generally being classified at high-risk; though not all existing risk scores are designed to be 
applicable at advanced ages.27
Model structure
A Markov model was designed including five health states: ‘At risk’, ‘Coronary Heart 
Disease’ (CHD), ‘Stroke’ (STR), ‘Type 2 Diabetes Mellitus’ (DM) and ‘Dead’. Each state 
was further subdivided by single year of age and gender (Figure 1). Falls associated with 
AHT were accounted for in each cycle of the model as a potential adverse event in very 
elderly populations.
Patient population and subgroup analyses
The base-case modelled population was gender stratified (35% males and 65% females) 
according to the composition of the over-80 CPRD population and the United Nations World 
Population Ageing estimates.28 Subgroup analyses were conducted by varying the starting 
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age and gender distribution in the model. The cost-effectiveness of AHT for secondary 
prevention was evaluated in a start population with CHD.
Data sources
Data used to populate the model were derived from epidemiological analysis of primary care 
electronic health records data from a cohort of participants registered with the UK’s Clinical 
Practice Research Datalink (CPRD). The CPRD is a nationally representative sample of 
approximately 680 primary care practices across the UK. Health care utilisation and costs, 
including prescriptions, were estimated for each health state from CPRD electronic health 
records, with linked secondary care Hospital Episode Statistics (HES) data. 29 30 A systematic 
review was conducted to obtain data for treatment effectiveness in the model.
Epidemiological and costing analyses
Age-specific estimates of incidence, mortality and costs for each health state were estimated 
from a cohort of 98,220 participants aged 80 years and older drawn from analysis of 
electronic health records with linked hospital episodes data. 30 31 These analyses provided 
empirical estimates to underpin the model that are broadly representative of the UK’s over-80 
population, including representation of frail and multi-morbid individuals. The study cohort 
provided 200,719 person-years for epidemiological and costing analysis at 80-89 years, 
95,431 person-years at 90-99 years, and 4,544 person-years at 100 years and older. Rates of 
incidence and mortality were estimated in a time-to-event framework using a Weibull 
survival model, providing transition probabilities for movement between health states in the 
Markov model (Supplementary Table 1). Variance estimates from the Weibull model were 
also be incorporated into a probabilistic sensitivity analysis (PSA) to assess uncertainty in the 
model. Survival analyses were completed using CPRD data from 2001-14. 
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Costs were estimated based on utilisation of primary care services in CPRD (general practice 
consultations, telephone consultations, home visits, emergency and out-of-hours 
consultations) and secondary care services in hospital episodes statistics (inpatient hospital 
admissions, outpatient visits, day case visits and emergency admissions), including 
prescriptions (Supplementary Table 2). Unit costs were derived from the NHS reference costs 
and the Personal Social Services Research Unit (PSSRU). A two-part regression model was 
employed, as reported previously 30, to determine mean annual costs for each health state, 
stratified by age. Falls costs were estimated similarly through epidemiological analysis of 
falls incidence and costs of falls in CPRD and HES, including all costs associated with a fall 
in a given year. This includes health care costs associated with any potential fractures 
following a fall.
Intervention effects and unit costs
Clinical effectiveness measures for over-80s were drawn from the HYVET trial 
(Supplementary Table 3). Treatment was associated with a 30% relative risk (RR) reduction 
in the rate of stroke (RR = 0.70, 95% CI: 0.49 to 1.01), a 39% reduction in the rate of stroke 
mortality (RR = 0.61, 95% CI: 0.38 to 0.99), a 34% reduction in CHD (RR = 0.66, 95% CI: 
0.53 to 0.82), and a 21% reduction (RR = 0.79, 95% CI: 0.65 to 0.95) in all-cause mortality.32 
33 It was assumed that any improvement in diabetes mortality was equivalent to the 
improvement in all-cause mortality, as these data for over-80s were not available. Based on 
systematic review evidence, we assumed no effect of AHT on diabetes incidence in the base-
case analysis, but a 19% reduction (RR=0.81, 95% CI 0.62 to 1.06) in diabetes incidence 34 
was employed in a sensitivity analysis from a sample aged greater than 65 years, in the 
absence of any data for over-80s. 
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The relative incidence of experiencing a fall, between treated and not treated individuals, was 
applied to the model based on a non-randomised epidemiological study by Tinetti et al.16 in 
the absence of trial data. Based on Tinetti et al., AHT was associated with a 40% relative 
increase in falls (RR = 1.40, 95% CI: 1.03 to 1.90) among a nationally representative sample 
of adults aged 70 years and older in the US, providing a conservative estimate for the model. 
Intervention costs of treatment with AHT were estimated at £51.87 per year using the British 
National Formulary and the CPRD drug dictionary, based on the drugs used in HYVET. Unit 
costs of primary care consultations were: GP consultation, £45; telephone consultation, £27; 
home consultation, £88.92; out-of-hours consultation, £45 35. Secondary care consultations 
included: day case, £721; inpatient, £2729.64; outpatient, £275; accident & emergency, 
£132.36 
Time horizon and discounting
All outcomes were modelled using a lifetime horizon with a one-year cycle length. Both costs 
and health outcomes were discounted at an annual rate of 3.5% 37.
Model outcomes
Health outcomes were valued using quality-adjusted life-years (QALYs) and utility values 
used to calculate QALYs were drawn from data published in a compendium of EuroQol five-
dimensional (EQ-5D) questionnaire utility values for the UK participants by health condition 
and age (Supplementary Table 4) 38. Costs (£, GBP) are presented from a health system 
perspective, adopting any health care, medical care and drug costs borne by the UK National 
Health Service.
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Sensitivity analysis
To characterise uncertainty, a univariate sensitivity analysis was conducted to assess the 
individual impact of changes in input parameters on the resulting ICER 39. Values were 
varied primarily based on 95% confidence intervals for parameter estimates. An alternative 
cost for falls was employed using a previously published estimate of cost in the 12 months 
following a fall 40, assuming that most excess costs would occur in the year after a fall.
A probabilistic sensitivity analysis was also conducted by applying distributional assumptions 
to each parameter, representing statistical uncertainty across all model inputs simultaneously, 
and randomly selecting values across 10,000 simulations. Annual transition probabilities for 
the model were obtained by sampling from normal distributions using EHR-derived estimates 
as inputs. Beta distributions were employed for utility data and gamma distributions for cost 
data 41. Relative risks were sampled using a lognormal distribution. 
Model validation
Model validation comprised face validity (setting parameters to extreme values to assess 
predictable effects on outputs), internal validity (consistency of results across software 
platforms, Excel and R) and external validity (review by external experts). The base case 
model was built in both Excel and R, while the probabilistic sensitivity analyses was run in R 
for improved computational time.
Ethics
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The use of fully anonymized CPRD data was approved by the Medicines and Healthcare 
products Regulatory Agency’s Independent Scientific Advisory Committee (Protocol number 
15_047).
RESULTS
In the base case, the model start population comprised 1,000 individuals aged 80 years 
without long-term conditions, including 650 women and 350 men. AHT was associated with 
an overall increase of 725 QALYs per 1000 individuals entering the model, compared to no 
treatment, with 7,025 lifetime QALYs per 1000 (4,731 for females, 2,294 for males) in the 
treatment group and 6,300 lifetime QALYs per 1000 (4,256 for females, 2,044 for males) in 
the control group (Table 1). AHT was associated with an increased cost of £4.3 million per 
1000 individuals compared to no treatment, with costs equating to £32.4 million per 1000 in 
the treatment group (£21.2 million for females, £11.2 million for males) and £28.1 million in 
the control group (£18.4 million for females, £9.7 million for males). The cost of falls 
amounted to £1.1 million per 1000 in the treatment group and £684,542 per 1000 in the 
control group, indicating higher falls cost in those taking AHT compared to those not on 
AHT. AHT, in comparison with no treatment, was associated with a decrease in the number 
of life-years lived with CHD and stroke, but an increase in the number of years lived with 
diabetes resulting from longer duration survival with AHT. The additional lifetime health 
care costs per 1000 associated with an increase of 23.6 person years lived with diabetes were 
£125,482 (£750,522 in the treatment arm and £625,040 in the control arm). 
For an 80-year old individual, the additional lifetime cost of anti-hypertensive treatment was 
£4,334 for an additional 0.725 QALYs gained. The estimated incremental cost-effectiveness 
ratio (ICER) (lifetime cost per QALY) for AHT in the base-case was £5,977 per QALY 































































CONFIDENTIAL - NOT FOR DISTRIBUTION
11
(Table 1). Considering the UK’s willingness-to-pay (WTP) threshold range of £20,000-
30,000 per QALY, AHT can be considered cost-effective in over-80s even after accounting 
for the costs of adverse events through falls. While treatment appeared to be slightly less 
cost-effective for males than females, the ICERs for both were still well below the UK’s 
threshold range (£5,910 per QALY in females; £6,105 per QALY in males). If the WTP 
threshold were £30,000 per QALY, the net monetary benefit (NMB) to the health service 
associated with AHT in over-80s is valued at approximately £17.4 million per 1000 
individuals, or £10.2 million if each QALY gained is valued at £20,000 (Table 1).
Characterising uncertainty
In a one-way sensitivity analysis, cost-effectiveness was most sensitive to changes in the cost 
of falls (Figure 2). Despite varying this most influential parameter in the model, the ICER 
remained below the threshold range for cost-effectiveness. Increasing the annual falls cost 
from £1,300 in the base case to £6,696 in the deterministic sensitivity analysis resulted in an 
increased ICER of £8,364 per QALY. The relative risk reduction for stroke was also an 
influential model parameter. When varying this value to indicate a smaller difference in 
stroke rates between groups, the ICER increased to £7,058 per QALY, also remaining cost-
effective. With a lower limit of 0.49, indicating a greater stroke reduction with treatment, the 
ICER decreased to £5,287 per QALY. Changes in the discount rate and utility values had 
minimal effect on cost-effectiveness, as the ICER remained between £5,887 and £6,111 per 
QALY with variations in these parameters. Sensitivity of the ICER to selected input 
parameters is summarised in Figure 2.
Probabilistic sensitivity and subgroup analysis
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The base-case probabilistic model for over-80s yielded an ICER of £6,146 per QALY (95% 
uncertainty interval (UI) £5,291 to £7,446), and subgroup analysis indicated slightly greater 
cost-effectiveness in females (£6,074 per QALY, 95% UI £4,955 to £8,218) compared to 
males (£6,281 per QALY, 95% UI £5,057 to £8,398) (Table 2). Uncertainty intervals 
represent the 95% range for estimates from all simulations. Incremental differences in costs 
and QALYs between comparator groups for 10,000 simulations are presented in a cost-
effectiveness plane (Figure 3, left panel). With all points falling below the £30,000 per 
QALY and £20,000 per QALY thresholds, treatment remained cost-effective after accounting 
for distributional uncertainty in all model parameters. 
When evaluating older age sub-groups, the ICER remained below the threshold for cost-
effectiveness, at £6,521 per QALY in over-90s and £5,759 per QALY in over-100s. 
Treatment was most cost-effective in centenarians overall (95% UI £5,025 to £7,071). AHT 
was more cost-effective for females over 80 and 90 years, but cost-effectiveness was greater 
for males over 100 years.
AHT for secondary prevention of CVDs was less cost-effective compared to primary 
prevention, with an ICER of £9,903 per QALY (95% UI £9,364 to £12,322) in over-80s and 
£11,102  per QALY in over-90s. While primary prevention with AHT was more cost-
effective than treatment for secondary prevention, both can be considered cost-effective 
options based on the UK’s threshold range. Age-specific cost-effectiveness acceptability 
curves summarise uncertainty in the estimates of cost-effectiveness by age (Figure 3, right 
panel). AHT proved to be cost-effective in all age-groups 100% of the time, with the 
probability of being cost-effective equal to 1.00 (over-80s and over-100s) or 0.999 (over-90s) 
at a WTP threshold of £30,000 per QALY. 
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DISCUSSION
This research drew on empirical electronic health records data to model the cost-effectiveness 
of AHT in individuals aged 80 years and older. The study incorporated several novel aspects. 
This is the first study in this age-group to incorporate quality of life by using QALYs as an 
outcome measure to evaluate cost-effectiveness of AHT. The only other existing economic 
evaluation of AHT in over-80s used life years as its main health outcome in a Swiss 
context.23 Our model is also the first of its kind to account for falls as a potential adverse 
event in the evaluation of cost-effectiveness, a significant concern and cost driver in the very 
elderly. Increased QALYs associated with treatment resulted from lower incidence of CHD 
and stroke and reduced cardiovascular mortality. Higher costs in the treatment group arose 
primarily from increased longevity associated with AHT, but also from increased falls costs 
captured as an adverse consequence of treatment at advanced ages. 
AHT was highly cost-effective in this older age-group aged 80 years and over, even after 
accounting for uncertainty in all model parameters. This conclusion should be cautiously 
limited to relatively fit over-80s, as our estimates for treatment effectiveness originate from 
HYVET participants with few comorbidities and low levels of frailty. Treatment was more 
cost-effective in centenarian men compared to women, likely because they incur less 
incremental cost increase from treatment as a result of being typically healthier with less 
chronic morbidity compared to female centenarians.42-44
Cost-effectiveness was most sensitive to the relative risk for stroke and all-cause mortality 
estimates, and the cost of falls. Falls costs are difficult to measure at a population level 
because falls have wide ranging spectrums of severity and subsequent treatment or follow-up 
after an event can vary greatly. This will depend on the nature and scale of the fall (e.g. 
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impact on hip, head, femur, wrist) and the health status of the older individual experiencing 
the fall such as whether they experience multi-morbidity or polypharmacy. Despite the 
importance of falls in older populations, the cost of falls has not previously been incorporated 
in economic models evaluating the cost-effectiveness of AHT in the elderly, potentially 
indicating the scarcity of available data for this parameter.
Strengths and limitations
While economic evaluations are a widely used method to make trade-offs between costs and 
outcomes more explicit, these studies are scarce in over-80s for all treatment areas as there 
are less representative epidemiological data to inform estimates specific to this age-group. 
Findings from this study hold the strengths of using population-based nationally 
representative epidemiological data from a severely understudied elderly age-group.  This 
allowed for empirical estimates to underpin the model that are broadly representative of the 
UK’s over-80 population, including partial representation of frail and multi-morbid 
individuals.
The study is limited mostly by a scarcity of effectiveness and utility data specific to the 
general population of individuals over 80. Only one placebo-controlled trial has been 
conducted in this age-group, and mean utilities were attained for younger ages with an age 
decrement applied to extrapolate age-specific utilities beyond 80 years of age. Using this 
decrement approach for utilities may represent a limitation, as later years of life may not 
always correspond to decreases in quality of life, as we reported previously.31 44 This was 
however accounted for in sensitivity analyses where this age decrement was only applied up 
to 95 years, and did not have a large impact on the ICER. We did not assume a utility 
decrement associated with falls because of the high variability in falls outcomes. In addition, 
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there was no available falls disutility in the literature based on a generic preference-based 
measure that would consider all possible clinical outcomes. This approach is consistent with a 
previous cost-effectiveness model of bariatric surgery, where the cost of complications but 
not disutility associated with the complications were included because of a lack of data.45
This model did not include comorbidity health states, but this will be partially accounted for 
in the underlying population-based estimates of the model where existing comorbidities will 
be equally impactful in both groups. While we included the impact of falls incidence, we did 
not model any possible impact on renal function. Blood pressure lowering may sometimes 
contribute to renal insufficiency but AHT is also expected to reduce age-related decline in 
renal function. As with most economic evaluations, our model represented a simplification of 
the clinical reality. There are benefits from opting for less complex health economic models, 
to minimise the inevitable uncertainty based on data inputs. 
Given the estimates of treatment effect that underpin our model originate from HYVET, there 
are concerns regarding the generalisability of this evidence from a carefully selected group of 
older participants. Participants from HYVET were subject to several exclusions and are likely 
to be healthier than the general elderly hypertensive population. Hypertension treatment at 
the advanced age of 80 and older is often delivered in the context of frailty, multiple 
morbidity and polypharmacy and these vulnerable individuals are not fully represented in the 
trial data. Data from HYVET were used for all individuals in the model up to 100 years and 
over. We acknowledge that only 4.6% of HYVET patients were aged 90 years or over, but 
this trial currently provides the best available effectiveness data for modelling the cost-
effectiveness of AHT; trial effectiveness data are not presently available for centenarians as a 
sub-group.  All other estimates underpinning the model were obtained from a representative 
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population-based sample of over-80s, offering age-specific values of incidence and mortality 
rates up to 100 years and over, as well as age-specific costs, potentially offsetting these 
generalisability concerns. Additional sensitivity analysis also allowed for a wide range of 
uncertainty estimates.
Conclusions and what this study adds
Despite the importance of potential harms from medicines in over-80s, previous economic 
evaluations on AHT in this age-group have not incorporated adverse events, likely due to 
scarcity of data. This model acknowledges the additional costs of potential side effects from 
AHT use in the elderly, which may often result in falls from syncope, orthostatic hypotension 
and dizziness.
Our model adds to the limited existing literature by, firstly, using population-based UK 
estimates, secondly, accounting for adverse events through falls and, thirdly, using quality of 
life data allowing for QALYs to be used as the main health outcome measure in the model. 
The use of QALYs in our model allows decision makers to compare our findings with results 
from other clinical areas to make health care coverage decisions across a range of clinical 
areas. This study also demonstrates the cost-effectiveness of taking a population-based 
approach to condition management with age being the first indicator of treatment followed by 
decision-making around frailty rather than a more elaborate risk assessment process. 
Improved evidence concerning possible adverse outcomes of AHT in vulnerable older sub-
groups is still needed. As frailty levels increase, there may be more adverse events, fewer life 
expectancy gains, and lower incremental costs of AHT. There remains a need to estimate 
effectiveness of AHT at different levels of frailty before determining cost-effectiveness in 
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more vulnerable sub-groups of older people.
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Table 1: Results from base-case deterministic model per thousand persons.
Treatment No Treatment Incremental
Total discounted costs
  Overall £32,447,727 £28,113,532 £4,334,196
  Females £21,224,916 £18,413,859 £2,811,057
  Males £11,222,812 £9,699,673 £1,523,139
Total discounted QALYs
  Overall 7,025 6,300 725
  Females 4,731 4,256 476
  Males 2,294 2,044 249
Incremental Cost-Effectiveness Ratio
  Overall £5,977 per QALY
  Females £5,910 per QALY
  Males £6,105 per QALY
WTP threshold Net Monetary Benefit Net Health Benefit
(per 1,000 treated) (per 1,000 treated)
  £30,000 per QALY £17,415,804 580.5 QALYs 
  £20,000 per QALY £10,165,804 508.3 QALYs
WTP = willingness to pay
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Table 2: Incremental cost-effectiveness ratios (UK £ per QALY) and 95% uncertainty intervals from subgroup and probabilistic 
sensitivity analysis
Incremental cost-effectiveness ratio (95% uncertainty interval, UK£ per QALY)
80 years and over 90 years and over 100 years and over
Base-case model
  Overall 6,146 (5,291 to 7,446) 6,521 (5,772 to 7,829) 5,759 (5,025 to 7,071)
  Females only 6,074 (4,955 to 8,218) 6,410 (5,417 to 8,605) 5,880 (4,846 to 8,509)
  Males only 6,281 (5,057 to 8,398) 6,736 (5,672 to 8,678) 5,557 (4,681 to 7,600)
Secondary prevention
  Overall 9,903 (9,364 to 12,322) 11,102 (10,503 to 13,421) 11,003 (10,396 to 13,167)
  Females 9,727 (8,960 to 14,459) 10,846 (8,816 to 15,466) 10,876 (9,874 to 15,297)
  Males 10,244 (9,599 to 14,130) 11,598 (9,492 to 15,171) 11,231 (10,316 to 14,506)
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Legend for Figure 1: Schematic diagram of age-stratified Markov model. CHD, 
Coronary Heart Disease; STR, Stroke; DM, Diabetes Mellitus.
Legend for Figure 2: Tornado diagram of univariate sensitivity analysis. RR, relative 
risk; STR, stroke; CHD, coronary heart disease; DM, diabetes mellitus.
Legend for Figure 3: Cost-effectiveness plane and cost-effectiveness acceptability curve.
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Supplementary Table 1: Survival models (incidence and mortality) for age- and gender-
specific transition probabilities using CPRD data
Transition Regression modela
Healthy to CHD 𝑦 = ―18.4 ― 0.36𝑥 + 0.33𝑧 ― 0.002z2
Healthy to STR 𝑦 = ―7.3 ― 0.11𝑥 + 0.03𝑧
Healthy to DM 𝑦 = ―43.8 ― 0.22𝑥 + 1.1𝑧 ― 0.008𝑧2
Healthy to Dead 𝑦 = ―11.3 ― 0.28𝑥 + 0.10𝑧
CHD to Dead 𝑦 = 1.61 ― 0.29𝑥 ― 0.16𝑧 + 0.001𝑧2
STR to Dead 𝑦 = ―6.44 ― 0.13𝑥 + 0.06𝑧
DM to Dead 𝑦 = 23.75 ― 0.29𝑥 ― 0.73𝑧 + 0.005𝑧2
a x = Gender (female = 2, male = 1); z = Age
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Supplementary Table 2: Costs (UK £) of health care utilisation (including prescriptions) 
for Markov model from CPRD


































































































































CONFIDENTIAL - NOT FOR DISTRIBUTION
26
Supplementary Table 3: Intervention effects for Markov model
Condition Mean Relative Risk (RR) 95% CI Source
Incidence
Coronary heart disease 0.66 0.53 to 0.82
Beckett et al. 2008 
(HYVET Main Trial)
Stroke 0.70 0.49 to 1.01
Beckett et al. 2008 
(HYVET Main Trial)
Diabetes mellitus 1.00 1.00 to 1.00 N/A
Falls 1.40 1.03 to 1.90 Tinetti et al. 2014
Mortality
Coronary heart disease 0.77 0.60 to 1.01
Stroke 0.61 0.38 to 0.99
Diabetes mellitus 0.79 0.65 to 0.95
All cause death 0.79 0.65 to 0.95
Beckett et al. 2008 
(HYVET Main Trial)




Coronary heart disease 0.648a 0.02 Sullivan et al. 2011, ICD-9 414 
(Web Table 5 + age decrement)
Stroke 0.516 0.02 Sullivan et al. 2011, ICD-9 436 
(Web Table 5 + age decrement)
Diabetes mellitus 0.656 0.006 Sullivan et al. 2011, ICD-9 250 
(Web Table 5 + age decrement)
Healthy 0.818 0.008 Sullivan et al. 2011, MEPS 
General mean EQ-5D score 
(Web Table 1 + age decrement)
Age decrement -0.00027 0.0002 Sullivan et al. 2011, Age 
disutility covariate (Web Table 4)
a CHD utility at age 80 (using age decrement) = 0.651357[ICD-9 414, age 67] + (-0.00027*13)
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Schematic diagram of age-stratified Markov model. CHD, Coronary Heart Disease; STR, Stroke; DM, 
Diabetes Mellitus. 
136x79mm (300 x 300 DPI) 
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Tornado diagram of univariate sensitivity analysis. RR, relative risk; STR, stroke; CHD, coronary heart 
disease; DM, diabetes mellitus. 
118x73mm (300 x 300 DPI) 
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Cost-effectiveness plane and cost-effectiveness acceptability curve. 
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ABSTRACT 
Background: Blood pressure and anti-hypertensive treatment generally increase with age but 
there is uncertainty concerning the value of treatment at very advanced ages.
Objectives: This study aimed toTo estimate the cost-effectiveness of anti-hypertensive 
treatment (AHT) in people aged 80 years and over.
Methods: A Markov model compared AHT with no blood pressure treatment for the 
prevention of cardiovascular disease. Outcomes were new stroke, coronary heart disease and 
diabetes, with falls included as a potential complication of AHT. Costs were evaluated from a 
health system perspective. Incidence, mortality and costs of health care utilisation were 
estimated from linked primary and secondary care electronic health records for 98,220 
individuals aged 80 years and older. Clinical trial effectiveness estimates were from the 
Hypertension in the Very Elderly Trial (HYVET). Deterministic and probabilistic sensitivity 
analyses were conducted.
Results: In the base case, AHT for all individuals aged 80 and over, compared with no 
treatment, was associated with an additional 725 incremental quality adjusted life years 
(QALYs) and incremental health care costs of £4.3 million per 1000, with an incremental 
cost-effectiveness ratio (ICER) of £5977 per QALY. The ICER was most sensitive to the 
estimated cost of falls and the relative risk reduction in stroke incidence. Probabilistic 
sensitivity analysis gave 95% uncertainty intervals:  from £50575098 to £83988582 per 
QALY in men and £49554992 to £82188255 per QALY in women. AHT for secondary 
prevention in participants with CHD gave an ICER of £99039961 per QALY.
Conclusions: AHT is estimated to be cost-effective in individuals aged 80 years and over, 
even if health benefits are smaller or side effects costlier than in the base case. Benefits and 
harms for vulnerable sub-groups require further evaluation. 
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Highlights
What is already known about the topic?
 Blood pressure levels and treatment with anti-hypertensive therapy (AHT) increase 
with age but there is uncertainty concerning the value of treatment at very advanced 
ages beyond 80 years.
What does the paper add to existing knowledge?
 AHT in over-80s was associated with 725 incremental quality adjusted life years 
(QALYs) and incremental health care costs of £4.3 million per 1000, resulting in an 
incremental cost-effectiveness ratio (ICER) of £5977 per QALY. The ICER estimate 
was sensitive to the costs of treatment-associated falls but AHT was considered cost-
effective in over-80s even if side effects are more costly than in the base case. 
What insights does the paper provide for informing health care-related decision making? 
 Treatment for hypertension over the age of 80 years is cost-effective after accounting 
for falls, with a high probability of health benefit at acceptable cost even under less 
favourable assumptions. These findings may contribute new information to inform 
guidelines for treating hypertension in over-80s.
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INTRODUCTION
High blood pressure (BP), or clinical hypertension, is the most important risk factor for 
cardiovascular diseases (CVDs) including stroke, heart failure and myocardial infarction 1 2. 
Blood pressure levels generally increase with age 3 4 and the prevalence of hypertension and 
treatment with antihypertensive therapy (AHT) is very high in older adults, despite 
uncertainties concerning the risks and benefits of treatment at advanced ages.5 6 The 
occurrence of CVD has also shifted to older ages. CVDs now represent one of the most costly 
disease categories, with direct costs of $555 billion in the United States (US) in 2016 and £19 
billion annually in the United Kingdom (UK).7 8
While many studies have provided evidence of the effectiveness of AHT for cardiovascular 
prevention in middle-aged adults, the evidence at older ages is less clear. Several studies have 
reported benefits of AHT in people over 60 years, particularly for prevention of stroke, 9-12 
but potential benefits in people aged over 80 years are less well-established. The 
HYpertension in the Very Elderly Trial (HYVET) 13 is the only placebo-controlled trial to 
evaluate the effectiveness  of AHT in participants aged 80 years or older. The HYVET trial 
provided evidence of reduction in stroke incidence and mortality, as well as lower all-cause 
mortality, with AHT. 13 Eligible participants in HYVET may have had less comorbidity than 
in a general population sample of older adults but the HYVET investigators found no 
evidence that the intervention effect depended on frailty level. 14 In the Systolic Blood 
Pressure Intervention Trial (SPRINT), which employed a treat-to-target BP strategy in 
participants aged 75 and over, AHT was associated with lower rates of CVD events and 
lower all-cause mortality, but intervention was associated with slightly higher rates of kidney 
injury and syncope.15 Non-randomiszed epidemiological studies report that comorbidity and 
frailty are frequent in this age-group, consequently adverse effects including orthostatic 
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hypotension and falls assume greater importance at older ages.5 16 Many authors emphasize 
the importance of considering adverse events, cautioning against aggressive BP-lowering in 
the very elderly.17 18
Guidelines for treating hypertension in older people are inconsistent. The American Heart 
Association (AHA) and American College of Cardiology (ACC) recently recommended that 
the threshold systolic blood pressure (SBP) level for initiating treatment in over-65s should 
be reduced from 140 mm Hg to 130 mm Hg. 19 20 In contrast, the American College of 
Physicians (ACP) and the American Academy of Family Physicians (AAFP) recommend the  
SBP threshold of 150 mm Hg in over-60s 21, consistent with the National Institute for Care 
Excellence (NICE) recommendations in the UK for over-80s.22 In the absence of sufficient 
evidence, it is uncertain which individuals should be classified as hypertensive and treated 
with AHT. Improved evidence on the cost-effectiveness of AHT in over-80s may help to 
inform this debate.
One previous health economic evaluation 23 was conducted in the age-group over 80 years, 
evaluating cost-effectiveness of AHT from a Swiss health care perspective. This Swiss study 
used life-years as its main health outcome and concluded that treatment was cost-effective. 
However, the data available for analysis suffered from several limitations. The study did not 
estimate quality adjusted life years as a preferred outcome; costs were extrapolated from 
studies in younger age-groups; and adverse events were not accounted for. The present study 
aimed to add to this limited evidence base, by estimating the cost-effectiveness of AHT in 
individuals aged 80 years and older. The study draws on empirical data from the UK through 
epidemiological analysis of electronic health records. These analyses provided population-
based estimates for the probability of transitioning between each of the model’s health states. 
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Analyses also provided empirical estimates for health care resource use. Potential adverse 
events from treatment were also accounted for in the model through the inclusion of falls. 
METHODS
Intervention comparators
Cost-effectiveness of universal AHT, using a diuretic and an ACE-inhibitor if needed, was 
evaluated in comparison with no AHT. A population-wide strategy in which all individuals 
over 80 years are treated is justified by clinical guidelines, which generally recommend that 
treatment for hypertension should be based on individuals’ overall 10-year CVD risk.19 22 24-26 
Increasing age is the strongest predictor of risk, with all individuals aged 80 years and older 
generally being classified at high-risk,; though not all existing risk scores are designed to be 
applicable at advanced ages.27
Model structure
A Markov model was designed including five health states: ‘At risk’, ‘Coronary Heart 
Disease’ (CHD), ‘Stroke’ (STR), ‘Type 2 Diabetes Mellitus’ (DM) and ‘Dead’. Each state 
was further subdivided by single year of age and gender (Figure 1). Falls associated with 
AHT were accounted for in each cycle of the model as a potential adverse event in very 
elderly populations.
Patient population and subgroup analyses
The base-case modelled population was gender stratified (35% males and 65% females) 
according to the composition of the over-80 CPRD population and the United Nations World 
Population Ageing estimates.28 Subgroup analyses were conducted by varying the starting 
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age and gender distribution in the model. The cost-effectiveness of AHT for secondary 
prevention was evaluated in a start population with CHD.
Data sources
Data used to populate the model were derived from epidemiological analysis of primary care 
electronic health records data from a cohort of participants registered with the UK’s Clinical 
Practice Research Datalink (CPRD). The CPRD is a nationally representative sample of 
approximately 680 primary care practices across the UK. Health care utilisation and costs, 
including prescriptions, were estimated for each health state from CPRD electronic health 
records, with linked secondary care Hospital Episode Statistics (HES) data. 29 30 A systematic 
review was conducted to obtain data for treatment effectiveness in the model.
Epidemiological and costing analyses
Age-specific estimates of incidence, mortality and costs for each health state were estimated 
from a cohort of 98,220 participants aged 80 years and older drawn from analysis of 
electronic health records with linked hospital episodes data. 30 31 These analyses provided 
empirical estimates to underpin the model that are broadly representative of the UK’s over-80 
population, including representation of frail and multi-morbid individuals. The study cohort 
provided 200,719 person-years for epidemiological and costing analysis at 80-89 years, 
95,431 person-years at 90-99 years, and 4,544 person-years at 100 years and older. Rates of 
incidence and mortality were estimated in a time-to-event framework using a Weibull 
survival model, providing transition probabilities for movement between health states in the 
Markov model (Supplementary Table 1). Variance estimates from the Weibull model were 
also be incorporated into a probabilistic sensitivity analysis (PSA) to assess uncertainty in the 
model. Survival analyses were completed using CPRD data from 2001-14. 
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Costs were estimated based on utilisation of primary care services in CPRD (general practice 
consultations, telephone consultations, home visits, emergency and out-of-hours 
consultations) and secondary care services in hospital episodes statistics (inpatient hospital 
admissions, outpatient visits, day case visits and emergency admissions), including 
prescriptions (Supplementary Table 12). Unit costs were derived from the NHS reference 
costs and the Personal Social Services Research Unit (PSSRU). A two-part regression model 
was employed, as reported previously 30, to determine mean annual costs for each health 
state, stratified by age. Falls costs were also similarly estimated similarly through 
epidemiological analysis of falls incidence and costs of falls in CPRD and HES, including all 
costs associated with a fall in a given year. This includes health care costs associated with 
any potential fractures following a fall.
Intervention effects and unit costs
Clinical effectiveness measures for over-80s were drawn from the HYVET trial 
(Supplementary Table 23). Treatment was associated with a 30% relative risk (RR) reduction 
in the rate of stroke (RR = 0.70, 95% CI: 0.49 to 1.01), a 39% reduction in the rate of stroke 
mortality (RR = 0.61, 95% CI: 0.38 to 0.99), a 34% reduction in CHD (RR = 0.66, 95% CI: 
0.53 to 0.82), and a 21% reduction (RR = 0.79, 95% CI: 0.65 to 0.95) in all-cause mortality.32 
33 It was assumed that any improvement in diabetes mortality was equivalent to the 
improvement in all-cause mortality, as these data for over-80s were not available. Based on 
systematic review evidence, we assumed no effect of AHT on diabetes incidence in the base-
case analysis, but a 19% reduction (RR=0.81, 95% CI 0.62 to 1.06) in diabetes incidence 34 
was employed in a sensitivity analysis from a sample aged greater than> 65 years, in the 
absence of any data for over-80s. 
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The relative incidence of experiencing a fall, between treated and not treated individuals, was 
applied to the model based on a non-randomised epidemiological study by Tinetti et al.16 in 
the absence of trial data. Based on Tinetti et al., AHT was associated with a 40% relative 
increase in falls (RR = 1.40, 95% CI: 1.03 to 1.90) among a nationally representative sample 
of adults aged 70 years and older in the US, providing a conservative estimate for the model. 
Intervention costs of treatment with AHT were estimated at £51.87 per year using the British 
National Formulary and the CPRD drug dictionary, based on the drugs used in HYVET. Unit 
costs of primary care consultations were: GP consultation, £45; telephone consultation, £27; 
home consultation, £88.92; out-of-hours consultation, £45 35. Secondary care consultations 
included: day case, £721; inpatient, £2729.64; outpatient, £275; accident & emergency, 
£132.36 
Time horizon and discounting
All outcomes were modelled using a lifetime horizon with a one-year cycle length. Both costs 
and health outcomes were discounted at an annual rate of 3.5% 37.
Model outcomes
Health outcomes were valued using quality-adjusted life-years (QALYs) and utility values 
used to calculate QALYs were drawn from data published in a compendium of EuroQol five-
dimensional (EQ-5D) questionnaire utility values for the UK participants by health condition 
and age (Supplementary Table 4) 38. Costs (£, GBP) are presented from a health system 
perspective, adopting any health care, medical care and drug costs borne by the UK National 
Health Service.
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Sensitivity analysis
To characterise uncertainty, a univariate sensitivity analysis was conducted to assess the 
individual impact of changes in input parameters on the resulting ICER 39. Values were 
varied primarily based on 95% confidence intervals for parameter estimates. An alternative 
cost for falls was employed using a previously published estimate of cost in the 12 months 
following a fall 40, assuming that most excess costs would occur in the year after a fall.
A probabilistic sensitivity analysis was also conducted by applying distributional assumptions 
to each parameter, representing statistical uncertainty across all model inputs simultaneously, 
and randomly selecting values across 10,000 simulations. Annual transition probabilities for 
the model were obtained by sampling from normal distributions using EHR-derived estimates 
as inputs. Beta distributions were employed for utility data and gamma distributions for cost 
data 41. Relative risks were sampled using a lognormal distribution. 
Model validation
Model validation comprised face validity (setting parameters to extreme values to assess 
predictable effects on outputs), internal validity (consistency of results across software 
platforms, Excel and R) and external validity (review by external experts). The base case 
model was built in both Excel and R, while the probabilistic sensitivity analyses was run in R 
for improved computational time.
Ethics
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The use of fully anonymized CPRD data was approved by the Medicines and Healthcare 
products Regulatory Agency’s Independent Scientific Advisory Committee (Protocol number 
15_047).
RESULTS
In the base case, the model start population comprised 1,000 individuals aged 80 years 
without long-term conditions, including 650 women and 350 men. AHT was associated with 
an overall increase of 725 QALYs per 1000 individuals entering the model, compared to no 
treatment, with 7,025 lifetime QALYs per 1000 (4,731 for females, 2,294 for males) in the 
treatment group and 6,300 lifetime QALYs per 1000 (4,256 for females, 2,044 for males) in 
the control group (Table 1). AHT was associated with an increased cost of £4.3 million per 
1000 individuals compared to no treatment, with costs equating to £32.4 million per 1000 in 
the treatment group (£21.2 million for females, £11.2 million for males) and £28.1 million in 
the control group (£18.4 million for females, £9.7 million for males). The cost of falls 
amounted to £1.1 million per 1000 in the treatment group and £684,542 per 1000 in the 
control group, indicating higher falls cost in those taking AHT compared to those not on 
AHT. AHT, in comparison with no treatment, was associated with a decrease in the number 
of life-years lived with CHD and stroke, but an increase in the number of years lived with 
diabetes resulting from longer duration survival with AHT. The additional lifetime health 
care costs per 1000 associated with an increase of 23.6 person years lived with diabetes were 
£125,482 (£750,522 in the treatment arm and £625,040 in the control arm). 
For an 80-year old individual, the additional lifetime cost of anti-hypertensive treatment was 
£4,33400 for an additional 0.725 QALYs gained. The estimated incremental cost-
effectiveness ratio (ICER) (lifetime cost per QALY) for AHT in the base-case was £5,977 per 
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QALY (Table 1). Considering the UK’s willingness-to-pay (WTP) threshold range of 
£20,000-30,000 per QALY, AHT can be considered cost-effective in over-80s even after 
accounting for the costs of adverse events through falls. While treatment appeared to be 
slightly less cost-effective for males than females, the ICERs for both were still well below 
the UK’s threshold range (£5,910 per QALY in females; £6,105 per QALY in males). If the 
WTP threshold were £30,000 per QALY, the net monetary benefit (NMB) to the health 
service associated with AHT in over-80s is valued at approximately £17.4 million per 1000 
individuals, or £10.2 million if each QALY gained is valued at £20,000 (Table 1).
Characterising uncertainty
In a one-way sensitivity analysis, cost-effectiveness was most sensitive to changes in the cost 
of falls (Figure 2). Despite varying this most influential parameter in the model, the ICER 
remained below the threshold range for cost-effectiveness. Increasing the annual falls cost 
from £1,300 in the base case to £6,696 in the deterministic sensitivity analysis resulted in an 
increased ICER of £8,364 per QALY. The relative risk reduction for stroke was also an 
influential model parameter. When varying this value to indicate a smaller difference in 
stroke rates between groups, the ICER increased to £7,058 per QALY, also remaining cost-
effective. With a lower limit of 0.49, indicating a greater stroke reduction with treatment, the 
ICER decreased to £5,287 per QALY. Changes in the discount rate and utility values had 
minimal effect on cost-effectiveness, as the ICER remained between £5,887 and £6,111 per 
QALY with variations in these parameters. Sensitivity of the ICER to selected input 
parameters is summarised in Figure 2.
Probabilistic sensitivity and subgroup analysis
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The base-case probabilistic model for over-80s yielded an ICER of £6,176 146 per QALY 
(95% uncertainty interval (UI) £5,350 291 to £7,532446), and subgroup analysis indicated 
slightly greater cost-effectiveness in females (£6,096 074 per QALY, 95% UI £4,992 955 to 
£8,21855) compared to males (£6,328 281 per QALY, 95% UI £5,098 057 to £8,582398) 
(Table 32). Uncertainty intervals represent the 95% range for estimates from all simulations. 
Incremental differences in costs and QALYs between comparator groups for 10,000 
simulations are presented in a cost-effectiveness plane (Figure 3, left panel). With all points 
falling below the £30,000 per QALY and £20,000 per QALY thresholds, treatment remained 
cost-effective after accounting for distributional uncertainty in all model parameters. 
When evaluating older age sub-groups, the ICER remained below the threshold for cost-
effectiveness, at £6,526 521 per QALY in over-90s and £5,759 per QALY in over-100s. 
Treatment was most cost-effective in centenarians overall (95% UI £5,013 025 to 
£7,155071). AHT was more cost-effective for females over 80 and 90 years, but cost-
effectiveness was greater for males over 100 years.
AHT for secondary prevention of CVDs was less cost-effective compared to primary 
prevention, with an ICER of £9,903892 per QALY (95% UI £9,368 364 to £12,294322) in 
over-80s and £11,103 102 ($14,989) per QALY in over-90s. While primary prevention with 
AHT was more cost-effective than treatment for secondary prevention, both can be 
considered cost-effective options based on the UK’s threshold range. Age-specific cost-
effectiveness acceptability curves summarise uncertainty in the estimates of cost-
effectiveness by age (Figure 3, right panel). AHT proved to be cost-effective in all age-
groups 100% of the time, with the probability of being cost-effective equal to 1.00 (over-80s 
and over-100s) or 0.999 (over-90s) at a WTP threshold of £30,000 per QALY. 
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DISCUSSION
This research drew on empirical electronic health records data to model the cost-effectiveness 
of AHT in individuals aged 80 years and older. The study incorporated several novel aspects. 
This is the first study in this age-group to incorporate quality of life by using QALYs as an 
outcome measure to evaluate cost-effectiveness of AHT. The only other existing economic 
evaluation of AHT in over-80s used life years as its main health outcome in a Swiss 
context.23 Our model is also the first of its kind to account for falls as a potential adverse 
event in the evaluation of cost-effectiveness, a significant concern and cost driver in the very 
elderly. Increased QALYs associated with treatment resulted from lower incidence of CHD 
and stroke and reduced cardiovascular mortality. Higher costs in the treatment group arose 
primarily from increased longevity associated with AHT, but also from increased falls costs 
captured as an adverse consequence of treatment at advanced ages. 
AHT was highly cost-effective in this older age-group aged 80 years and over, even after 
accounting for uncertainty in all model parameters. This conclusion should be cautiously 
limited to relatively fit over-80s, as our estimates for treatment effectiveness originate from 
HYVET participants with few comorbidities and low levels of frailty. Treatment was more 
cost-effective in centenarian men compared to women, likely because they incur less 
incremental cost increase from treatment as a result of being typically healthier with less 
chronic morbidity compared to female centenarians.42-44
Cost-effectiveness was most sensitive to the relative risk for stroke and all-cause mortality 
estimates, and the cost of falls. Falls costs are difficult to measure at a population level 
because falls have wide ranging spectrums of severity and subsequent treatment or follow-up 
after an event can vary greatly. This will depend on the nature and scale of the fall (e.g. 
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impact on hip, head, femur, wrist) and the health status of the older individual experiencing 
the fall such as whether they experience multi-morbidity or polypharmacy. Despite the 
importance of falls in older populations, the cost of falls has not previously been incorporated 
in economic models evaluating the cost-effectiveness of AHT in the elderly, potentially 
indicating the scarcity of available data for this parameter.
Strengths and limitations
While economic evaluations are a widely used method to make trade-offs between costs and 
outcomes more explicit, these studies are scarce in over-80s for all treatment areas as there 
are less representative epidemiological data to inform estimates specific to this age-group. 
Findings from this study hold the strengths of using population-based nationally 
representative epidemiological data from a severely understudied elderly age-group.  This 
allowed for empirical estimates to underpin the model that are broadly representative of the 
UK’s over-80 population, including partial representation of frail and multi-morbid 
individuals. 
The study is limited mostly by a scarcity of effectiveness and utility and effectiveness data 
specific to the general population of individuals over 80. Only one placebo-controlled trial 
has been conducted in this age-group, and mean utilities were attained for younger ages with 
an age decrement applied to extrapolate age-specific utilities beyond 80 years of age. Using 
this decrement approach for utilities may represent a limitation, as later years of life may not 
always correspond to decreases in quality of life, as we reported previously.31 44. This was 
however accounted for in sensitivity analyses where this age decrement was only applied up 
to 95 years, and did not have a large impact on the ICER. We did not assume a utility 
decrement associated with falls because of the high variability in falls outcomes. In addition, 
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there was no available falls disutility in the literature based on a generic preference-based 
measure that would consider all possible clinical outcomes. This approach is consistent with a 
previous cost-effectiveness model of bariatric surgery, where the cost of complications but 
not disutility associated with the complications were included because of a lack of data.45
This model did not include comorbidity health states, but this will be partially accounted for 
in the underlying population-based estimates of the model where existing comorbidities will 
be equally impactful in both groups. While we included the impact of falls incidence, we did 
not model any possible impact on renal function. Blood pressure lowering may sometimes 
contribute to renal insufficiency but AHT is also expected to reduce age-related decline in 
renal function. As with most economic evaluations, our model represented a simplification of 
the clinical reality. There are benefits from opting for less complex health economic models, 
to minimise the inevitable uncertainty based on data inputs. 
Given the estimates of treatment effect that underpin our model originate from HYVET, there 
are concerns regarding the generalisability of this evidence from a carefully selected group of 
older participants. Participants from HYVET were subject to several exclusions and are likely 
to be healthier than the general elderly hypertensive population. Hypertension treatment at 
the advanced age of 80 and older is often delivered in the context of frailty, multiple 
morbidity and polypharmacy and these vulnerable individuals are not fully represented in the 
trial data. Data from HYVET were used for all individuals in the model up to 100 years and 
over. HYVET We acknowledge that only 4.6% of HYVET patients were aged 90 years or 
over, but this trial currentlystill provides the best available treatment effectiveness data from 
a randomised placebo-controlled trial in this age-group for modelling the cost-effectiveness 
of AHT;. trial effectiveness data are not presently available for centenarians as a sub-group.  
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All other estimates underpinning the model were obtained from a representative population-
based sample of over-80s, offering age-specific values of incidence and mortality rates up to 
100 years and over, as well as age-specific costs,  potentially offsetting these generalisability 
concerns. Additional sensitivity analysis also allowed for a wide range of uncertainty 
estimates.
Conclusions and what this study adds
Despite the importance of potential harms from medicines in over-80s, previous economic 
evaluations on AHT in this age-group have not incorporated adverse events, likely due to 
scarcity of data. This model acknowledges the additional costs of potential side effects from 
AHT use in the elderly, which may often result in falls from syncope, orthostatic hypotension 
and dizziness.
Our model adds to the limited existing literature by, firstly, using population-based UK 
estimates, secondly, accounting for adverse events through falls and, thirdly, using quality of 
life data allowing for QALYs to be used as the main health outcome measure in the model. 
The use of QALYs in our model allows decision makers to compare our findings with results 
from other clinical areas to make health care coverage decisions across a range of clinical 
areas. This study also demonstrates the cost-effectiveness of taking a population-based 
approach to condition management with age being the first indicator of treatment followed by 
decision-making around frailty rather than a more elaborate risk assessment process. 
Improved evidence concerning possible adverse outcomes of AHT in vulnerable older sub-
groups is still needed. As frailty levels increase, there may be more adverse events, fewer life 
expectancy gains, and lower incremental costs of AHT. There remains a need to estimate 































































CONFIDENTIAL - NOT FOR DISTRIBUTION
18
effectiveness of AHT at different levels of frailty before determining cost-effectiveness in 
more vulnerable sub-groups of older people.
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Table 1: Results from base-case deterministic model per thousand persons.
Treatment No Treatment Incremental
Total discounted costs
  Overall £32,447,727 £28,113,532 £4,334,196
  Females £21,224,916 £18,413,859 £2,811,057
  Males £11,222,812 £9,699,673 £1,523,139
Total discounted QALYs
  Overall 7,025 6,300 725
  Females 4,731 4,256 476
  Males 2,294 2,044 249
Incremental Cost-Effectiveness Ratio
  Overall £5,977 per QALY
  Females £5,910 per QALY
  Males £6,105 per QALY
WTP threshold Net Monetary Benefit Net Health Benefit
(per 1,000 treated) (per 1,000 treated)
  £30,000 per QALY £17,415,804 580.5 QALYs 
  £20,000 per QALY £10,165,804 508.3 QALYs
WTP = willingness to pay
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Table 2: Incremental cost-effectiveness ratios (UK £ per QALY) and 95% uncertainty intervals from subgroup and probabilistic 
sensitivity analysis
Incremental cost-effectiveness ratio (95% uncertainty interval, UK£ per QALY)
80 years and over 90 years and over 100 years and over
Base-case model
  Overall 6,1466,176 (5,3505,291 to 
7,4467,532)
6,526 521 (5,77299 to 
7,8297844)
5,759 (5,013 5,025 to 7,1557,071)
  Females only 6,0966,074 (4,9924,955 to 
8,2558,218)
6,41002 (5,417383 to 
8,605556)
5,8808 (4,84600 to 8,509846)
  Males only 6,3286,281 (5,0985,057 to 
8,5828,398)
6,73661 (5,67264 to 
8,678815)
5,5575,546 (4,6814,691 to 7,6007,174)
Secondary prevention
  Overall 9,8929,903 (9,3649368 to 
12,32212,294)
11,1023 (10,50311 to 
13,4216)
11,023 003 (10,39670 to 13,167688)
  Females 9,7169,727 (90068,960 to 
14,45916,239)
10,8469 (8,816855 to 
154,466306)
10,907 876 (6430 9,874 to 15,29744)
  Males 10,24410,235 (9,5996852 
to 14,13013,334)
11,598608 (9,49210,991 to 
154,789171)
11,23123 (10,316432 to 14,506283)
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Legend for Figure 1: Schematic diagram of age-stratified Markov model. CHD, 
Coronary Heart Disease; STR, Stroke; DM, Diabetes Mellitus.
Legend for Figure 2: Tornado diagram of univariate sensitivity analysis. RR, relative 
risk; STR, stroke; CHD, coronary heart disease; DM, diabetes mellitus.
Legend for Figure 3: Cost-effectiveness plane and cost-effectiveness acceptability curve.
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Supplementary Table 1: Survival models (incidence and mortality) for age- and gender-
specific transition probabilities using CPRD data
Transition Regression modela
Healthy to CHD 𝑦 = ―18.4 ― 0.36𝑥 + 0.33𝑧 ― 0.002𝑧2
Healthy to STR 𝑦 = ―7.3 ― 0.11𝑥 + 0.03𝑧
Healthy to DM 𝑦 = ―43.8 ― 0.22𝑥 + 1.1𝑧 ― 0.008𝑧2
Healthy to Dead 𝑦 = ―11.3 ― 0.28𝑥 + 0.10𝑧
CHD to Dead 𝑦 = 1.61 ― 0.29𝑥 ― 0.16𝑧 + 0.001𝑧2
STR to Dead 𝑦 = ―6.44 ― 0.13𝑥 + 0.06𝑧
DM to Dead 𝑦 = 23.75 ― 0.29𝑥 ― 0.73𝑧 + 0.005𝑧2
a x = Gender (female = 2, male = 1); z = Age
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Supplementary Table 2: Costs (UK £) of health care utilisation (including prescriptions) 
for Markov model from CPRD
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Supplementary Table 3: Intervention effects for Markov model
Condition Mean Relative Risk (RR) 95% CI Source
Incidence
Coronary heart disease 0.66 0.53 to 0.82
Beckett et al. 2008 
(HYVET Main Trial)
Stroke 0.70 0.49 to 1.01
Beckett et al. 2008 
(HYVET Main Trial)
Diabetes mellitus 1.00 1.00 to 1.00 N/A
Falls 1.40 1.03 to 1.90 Tinetti et al. 2014
Mortality
Coronary heart disease 0.77 0.60 to 1.01
Stroke 0.61 0.38 to 0.99
Diabetes mellitus 0.79 0.65 to 0.95
All cause death 0.79 0.65 to 0.95
Beckett et al. 2008 
(HYVET Main Trial)




Coronary heart disease 0.648a 0.02 Sullivan et al. 2011, ICD-9 414 
(Web Table 5 + age decrement)
Stroke 0.516 0.02 Sullivan et al. 2011, ICD-9 436 
(Web Table 5 + age decrement)
Diabetes mellitus 0.656 0.006 Sullivan et al. 2011, ICD-9 250 
(Web Table 5 + age decrement)
Healthy 0.818 0.008 Sullivan et al. 2011, MEPS 
General mean EQ-5D score 
(Web Table 1 + age decrement)
Age decrement -0.00027 0.0002 Sullivan et al. 2011, Age 
disutility covariate (Web Table 4)
a CHD utility at age 80 (using age decrement) = 0.651357[ICD-9 414, age 67] + (-0.00027*13)
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Reviewer: 1
The authors performed a cost-utility analysis of anti-hypertensive treatment for the elderly. In general, 
the paper is well-written and tackles an interesting topic, while most RCTs target a relatively young 
population, the drugs are prescribed in much older patients in practice. Assessing the cost-effectiveness 
for this older population is valuable and should be done more often.
Although the model seems well-designed, this is not easily checked, as key parameters are missing from 
the manuscript, such as the transition probabilities. Please include a comprehensive table with all key 
model parameters included. Additionally, the supplementary tables are not included with this proof, 
likely containing further model parameters.
Response: Thank you for taking the time to review our paper. We have now included all key parameters 
in the supplementary tables, including survival models for calculating age- and gender-specific transition 
probabilities. Costs, utilities and relative risk estimates are also provided.
The patients included in the HYVET trial were primarily aged 80-90. It is unclear to me how these data 
were adapted to include a population aged 100 and over. In general, the question arises whether 
centennials should start with antihypertensive treatment in the first place, for which clinical evidence is 
lacking.
Response: Thank you for highlighting this. We have added to the Limitations section in the Discussion 
(page 15, paragraph 3): “Data from HYVET were used for all individuals in the model up to 100 years and 
over. We acknowledge that only 4.6% of HYVET patients were aged 90 years or over but this trial 
currently provides the best available effectiveness data for modelling the cost-effectiveness of AHT; trial 
effectiveness data are not presently available for centenarians as a sub-group. All other estimates 
underpinning the model were obtained from a representative population-based sample of over-80s, 
offering age-specific values of incidence and mortality rates up to 100 years and over, as well as age-
specific costs, potentially offsetting these generalisability concerns.”
Minor comments:
While it is commendable that falls have been included as an adverse effect, the long-term complications 
of a potential fracture following a fall, may have a large impact on the model, as the model is very 
sensitive to the costs associated with falls. 
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Response: Thank you for raising this important point. We used a two-part model to determine a mean 
annual cost for those who experienced a fall. This includes all health care costs associated with a fall, 
including any potential fractures following a fall. We have added to the Methods section (page 7, 
paragraph 1): “Falls costs were estimated similarly through epidemiological analysis of falls incidence 
and cost of falls in CPRD and HES, including all costs associated with a fall in a given year. This includes 
health care costs associated with any potential fractures following a fall.”
Additionally, I am quite interested in the utility decrement for falls.
Response: We agree, this is a very good point. A section has been added to the Limitations section 
discussing this (page 14, paragraph 3): “We did not assume a utility decrement associated with falls 
because of the high variability in falls outcomes. In addition, there was no available falls disutility in the 
literature based on a generic preference-based measure that would consider all possible clinical 
outcomes. This approach is consistent with a previous cost-effectiveness model of bariatric surgery, 
where the cost of complications but not disutility associated with the complications were included 
because of a lack of data.”
1,000 Monte Carlo simulations have been included for the probabilistic sensitivity analysis, while 
currently 10,000 seems more common. Please elaborate on the choice to include 1,000.
Response: Thank you for this comment. We have now run the probabilistic sensitivity analysis using 
10,000 Monte Carlo simulations. The cost-effectiveness plane and cost-effectiveness acceptability 
curves in Figure 3, as well as the PSA results in Table 2 and in the text, have been updated accordingly.
Parts of the model are built using Excel and parts using R, please explain what is used for what.
Response: The deterministic model was built in Excel and this was replicated in R, providing one of three 
forms of validation. The probabilistic sensitivity analyses was run only in R as this was a more efficient 
computing environment for running Monte Carlo simulations. A sentence has been added to the 
Methods under the Model Validation section (page 9, paragraph 3): “The base case model was built in 
both Excel and R, while the probabilistic sensitivity analyses was run in R for improved computational 
time.”































































CONFIDENTIAL - NOT FOR DISTRIBUTION
One of the results of the model is the increase in years lived with diabetes, what are the costs associated 
with this increase?
Response: We have now added a sentence to the results outlining the costs associated with the increase 
in life years lived with diabetes (page 10, paragraph 2): “The additional lifetime health care costs per 
1000 associated with an increase of 23.6 person years lived with diabetes were £125,482 (£750,522 in 
the treatment arm and £625,040 in the control arm).”
It would be nice to add a £20,000 threshold to Figure 3.
Response: Thank you for this suggestion. We have now added a £20,000 per QALY threshold to the cost-
effectiveness plane in Figure 3.
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Supplementary Table 1: Survival models (incidence and mortality) for age- and gender-
specific transition probabilities using CPRD data
Transition Regression modela
Healthy to CHD 𝑦 = ―18.4 ― 0.36𝑥 + 0.33𝑧 ― 0.002z2
Healthy to STR 𝑦 = ―7.3 ― 0.11𝑥 + 0.03𝑧
Healthy to DM 𝑦 = ―43.8 ― 0.22𝑥 + 1.1𝑧 ― 0.008𝑧2
Healthy to Dead 𝑦 = ―11.3 ― 0.28𝑥 + 0.10𝑧
CHD to Dead 𝑦 = 1.61 ― 0.29𝑥 ― 0.16𝑧 + 0.001𝑧2
STR to Dead 𝑦 = ―6.44 ― 0.13𝑥 + 0.06𝑧
DM to Dead 𝑦 = 23.75 ― 0.29𝑥 ― 0.73𝑧 + 0.005𝑧2
a x = Gender (female = 2, male = 1); z = Age
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Supplementary Table 2: Costs (UK £) of health care utilisation (including prescriptions) 
for Markov model from CPRD
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Supplementary Table 3: Intervention effects for Markov model
Condition Mean Relative Risk (RR) 95% CI Source
Incidence
Coronary heart disease 0.66 0.53 to 0.82
Beckett et al. 2008 
(HYVET Main Trial)
Stroke 0.70 0.49 to 1.01
Beckett et al. 2008 
(HYVET Main Trial)
Diabetes mellitus 1.00 1.00 to 1.00 N/A
Falls 1.40 1.03 to 1.90 Tinetti et al. 2014
Mortality
Coronary heart disease 0.77 0.60 to 1.01
Stroke 0.61 0.38 to 0.99
Diabetes mellitus 0.79 0.65 to 0.95
All cause death 0.79 0.65 to 0.95
Beckett et al. 2008 
(HYVET Main Trial)




Coronary heart disease 0.648a 0.02 Sullivan et al. 2011, ICD-9 414 
(Web Table 5 + age decrement)
Stroke 0.516 0.02 Sullivan et al. 2011, ICD-9 436 
(Web Table 5 + age decrement)
Diabetes mellitus 0.656 0.006 Sullivan et al. 2011, ICD-9 250 
(Web Table 5 + age decrement)
Healthy 0.818 0.008 Sullivan et al. 2011, MEPS 
General mean EQ-5D score 
(Web Table 1 + age decrement)
Age decrement -0.00027 0.0002 Sullivan et al. 2011, Age 
disutility covariate (Web Table 4)
a CHD utility at age 80 (using age decrement) = 0.651357[ICD-9 414, age 67] + (-0.00027*13)
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